|
|
|
|
| LEADER |
01513nam a2200493Ia 4500 |
| 001 |
10-1016-j-eururo-2021-10-029 |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 03022838 (ISSN)
|
| 245 |
1 |
0 |
|a Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology
|
| 260 |
|
0 |
|b Elsevier B.V.
|c 2022
|
| 300 |
|
|
|a 2
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.eururo.2021.10.029
|
| 650 |
0 |
4 |
|a accuracy
|
| 650 |
0 |
4 |
|a androgen deprivation therapy
|
| 650 |
0 |
4 |
|a androgen receptor antagonist
|
| 650 |
0 |
4 |
|a artificial intelligence
|
| 650 |
0 |
4 |
|a biological marker
|
| 650 |
0 |
4 |
|a cancer center
|
| 650 |
0 |
4 |
|a cancer prognosis
|
| 650 |
0 |
4 |
|a clinical decision making
|
| 650 |
0 |
4 |
|a clinical trial (topic)
|
| 650 |
0 |
4 |
|a cross resistance
|
| 650 |
0 |
4 |
|a data base
|
| 650 |
0 |
4 |
|a docetaxel
|
| 650 |
0 |
4 |
|a Editorial
|
| 650 |
0 |
4 |
|a genomics
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a machine learning
|
| 650 |
0 |
4 |
|a male
|
| 650 |
0 |
4 |
|a medical record
|
| 650 |
0 |
4 |
|a metastatic castration resistant prostate cancer
|
| 650 |
0 |
4 |
|a metastatic castration sensitive prostate cancer
|
| 650 |
0 |
4 |
|a oncology
|
| 650 |
0 |
4 |
|a overall survival
|
| 650 |
0 |
4 |
|a personalized medicine
|
| 650 |
0 |
4 |
|a prostate cancer
|
| 650 |
0 |
4 |
|a prostate specific antigen
|
| 650 |
0 |
4 |
|a retinoblastoma protein
|
| 650 |
0 |
4 |
|a systemic therapy
|
| 650 |
0 |
4 |
|a taxane derivative
|
| 650 |
0 |
4 |
|a tumor-related gene
|
| 700 |
1 |
0 |
|a Beltran, H.
|e author
|
| 700 |
1 |
0 |
|a Morgans, A.K.
|e author
|
| 773 |
|
|
|t European Urology
|
